Mechanisms of autoimmunity in human diseases: A critical review of current dogma

Current Opinion in Rheumatology

Volumn 26, Issue 2, 2014, Pages 197-203

  Benson, Robert A ^a   Brewer, James M ^a   Platt, Andrew M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

antigen presentation; autoimmunity; dendritic cells; self tolerance

Indexed keywords

ANIMALS; ANTIGEN PRESENTATION; ARTHRITIS, RHEUMATOID; AUTOANTIGENS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MICE; MODELS, IMMUNOLOGICAL; SELF TOLERANCE;

EID: 84894029730     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000037     Document Type: Review

References (64)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205-2219
2. Raychaudhuri S, Remmers EF, Lee AT, et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 2008; 40:1216-1223
3. Raychaudhuri S, Thomson BP, Remmers EF, et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 2009; 41:1313-1318
4. Seidl C, Donner H, Fischer B, et al. CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens 1998; 51:62-66
5. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349:1907-1915
6. De Vita S, Zaja F, Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells. Arthritis Rheum 2002; 46:2029-2033
7. Hambleton S, Salem S, Bustamante J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 2011; 365:127-138
8. Ohnmacht C, Pullner A, King SB, et al. Constitutive ablation of dendritic cells breaks self-Tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med 2009; 206:549-559
9. Belkaid Y, Oldenhove G. Tuning microenvironments: Induction of regulatory T cells by dendritic cells. Immunity 2008; 29:362-371
10. Linterman MA, Liston A, Vinuesa CG. T-follicular helper cell differentiation and the co-option of this pathway by nonhelper cells. Immunol Rev 2012; 247:143-159
11. Tokoyoda K, Hauser AE, Nakayama T, Radbruch A. Organization of immunological memory by bone marrow stroma. Nat Rev Immunol 2010; 10:193-200
12. Benson RA, Patakas A, Conigliaro P, et al. Identifying the cells breaching selftolerance in autoimmunity. J Immunol 2010; 184:6378-6385
13. Teichmann LL, Ols ML, Kashgarian M, et al. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 2010; 33:967-978
14. Jongbloed SL, Lebre MC, Fraser AR, et al. Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther 2006; 8:R15
15. Lebre MC, Jongbloed SL, Tas SW, et al. Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP-dendritic cells with distinct cytokine profiles. Am J Pathol 2008; 172:940-950
16. van de Veerdonk FL, Lauwerys B, Marijnissen RJ, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011; 63:1507-1516
17. Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001; 167:4710-4718
18. Winchester RJ. Genetic aspects of rheumatoid arthritis. Springer Semin Immunopathol 1981; 4:89-102
19. Ling S, Cline EN, Haug TS, et al. Citrullinated calreticulin potentiates rheumatoid arthritis shared epitope signaling. Arthritis Rheum 2013; 65: 618-626
20. Law SC, Street S, Yu CH, et al. T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res Ther 2012; 14:R118
21. Scally SW, Petersen J, Law SC, et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med 2013
22. Orozco G, Sanchez E, Gonzalez-Gay MA, et al. Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 2005; 52:219-224
23. Cloutier JF, Veillette A. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 1999; 189:111-121
24. Sakaguchi N, Takahashi T, Hata H, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003; 426:454-460
25. Sugiyama D, Nishimura K, Tamaki K, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: A meta-Analysis of observational studies. Ann Rheum Dis 2010; 69:70-81
26. Kallberg H, Padyukov L, Plenge RM, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007; 80:867-875
27. Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008; 67:1488-1492
28. Klareskog L, Ronnelid J, Lundberg K, et al. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008; 26:651-675
29. Foulquier C, Sebbag M, Clavel C, et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007; 56:3541-3553
30. Harris ML, Darrah E, Lam GK, et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum 2008; 58:1958-1967
31. Reynisdottir G, Karimi R, Joshua V, et al. Structural lung changes and local anticitrulline immunity are early features of anti citrullinated-proteins antibodies positive rheumatoid arthritis. Arthritis Rheum 2013
32. Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nat Rev Rheumatol 2011; 7:569-578
33. Murakami M, Okuyama Y, Ogura H, et al. Local microbleeding facilitates IL-6-And IL-17-dependent arthritis in the absence of tissue antigen recognition by activated T cells. J Exp Med 2011; 208:103-114
34. Burman A, Haworth O, Hardie DL, et al. A chemokine-dependent stromal induction mechanism for aberrant lymphocyte accumulation and compromised lymphatic return in rheumatoid arthritis. J Immunol 2005; 174:1693-1700
35. Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011; 108:17372-17377
36. Ma J, Zhu C, Ma B, et al. Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis. Clin Dev Immunol 2012; 2012: 827480
37. Linterman MA, Beaton L, Yu D, et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med-2010; 207:353-363
38. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: Results of a systematic literature search. Ann Rheum Dis 2010; 69:638-643
39. Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013; 72:64-71
40. van den Broek M, Lems WF, Allaart CF. BeSt practice: The success of earlytargeted treatment in rheumatoid arthritis. Clin Exp Rheumatol 2012; 30 (4 Suppl 73):S35-S38
41. Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol 2012; 24:319-326
42. McGovern JL, Nguyen DX, Notley CA, et al. Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to antitumor necrosis factor antibody therapy. Arthritis Rheum 2012; 64:3129-3138
43. Teng YK, Wheater G, Hogan VE, et al. Induction of long-Term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity. Arthritis Res Ther 2012; 14:R57
44. Melet J, Mulleman D, Goupille P, et al. Rituximab-induced T-cell depletion in patients with rheumatoid arthritis: Association with clinical response. Arthritis Rheum 2013; 65:2783-2790
45. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143-2152
46. Pescovitz MD, Greenbaum CJ, Bundy B, et al. B-lymphocyte depletion with rituximab and beta-cell function: Two-year results. Diabetes Care 2013. [Epub ahead of print]
47. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012; 30:221-241
48. Evans JG, Chavez-Rueda KA, Eddaoudi A, et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007; 178:7868-7878
49. Carter NA, Vasconcellos R, Rosser EC, et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol 2011; 186:5569-5579
50. Flores-Borja F, Bosma A, Ng D, et al. CD19CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 2013; 5:173ra23
51. Fautrel B, Verstappen SM, Boonen A. Economic consequences and potential benefits. Best Pract Res Clin Rheumatol 2011; 25:607-624
52. Lang VR, Englbrecht M, Rech J, et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford) 2012; 51:852-857
53. Xie X, Li F, Chen JW, Wang J. Risk of tuberculosis infection in anti-TNF-Alpha biological therapy: From bench to bedside. J Microbiol Immunol Infect 2013. (10.1016/j.jmii.2013.03.005
54. Mijnheer G, Prakken BJ, van Wijk F. The effect of autoimmune arthritis treatment strategies on regulatory T-cell dynamics. Curr Opin Rheumatol 2013; 25:260-267
55. Lutterotti A, Yousef S, Sputtek A, et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: A phase 1 trial in multiple sclerosis. Sci Transl Med 2013; 5:ra75
56. Hippen KL, Merkel SC, Schirm DK, et al. Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versushost disease. Am J Transplant 2011; 11:1148-1157
57. Battaglia M, Roncarolo MG. Immune intervention with T regulatory cells: Past lessons and future perspectives for type 1 diabetes. Semin Immunol 2011; 23:182-194
58. Thomas R. Dendritic cells and the promise of antigen-specific therapy in rheumatoid arthritis. Arthritis Res Ther 2013; 15:204
59. Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis 2010; 69:2042-2050
60. Giannoukakis N, Trucco M. Dendritic cell therapy for Type 1 diabetes suppression. Immunotherapy 2012; 4:1063-1074
61. Giannoukakis N, Phillips B, Finegold D, et al. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011; 34:2026-2032
62. Butler NS, Moebius J, Pewe LL, et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol 2012; 13:188-195
63. Martin E, Capini C, Duggan E, et al. Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-kappaB. Arthritis Rheum 2007; 56:2255-2266
64. Hilkens CM, Isaacs JD. Tolerogenic dendritic cell therapy for rheumatoid arthritis: Where are we now? Clin Exp Immunol 2013; 172:148-157